CoronaVac and its positive results could not have arrived at a better time.
Beijing-based Sinovac Biotech Ltd. Released an official statement claiming its coronavirus shot is safe and capable of producing an immune response from human trials. This suggests the shot’s potential in defending against infection of the novel coronavirus.
More than 90% of people administered with the shot on a 14-day interval showed promising signs sans severe side effects. But even more importantly, results show that it’s induced neutralising antibodies two weeks after inoculation.
These preliminary findings come from phase I and II trials in China: a total of 743 healthy people ages 18 to 59 either received shots on two schedules or a placebo. More data will soon be uncovered from another group in the trial that received shots on a 28-day interval.
CoronaVac’s safe and effective potential in defending against the novel coronavirus is definitely good news for patients, medical experts and everyone else who has tied their hopes to a vaccine against COVID-19.
The vaccine is made using a killed version of the coronavirus. The vaccine is among five Chinese experimental shots that have reached the crucial final stage of human testing before they can be approved for public use.
The company announced a partnership this month with Instituto Butantan to conduct its phase III trial in Brazil, where the novel pathogen has caused the second-largest outbreak in a global pandemic that so far infected more than 7.7 million people and killed over 428,000.
This is one of the latest breakthroughs in the fight against the global viral spread – just the answer we might all be looking for.